World population estimates and History of the world Estimates of world population by their nature are an aspect of modernitypossible only since the Age of Discovery. Early estimates for the population of the world  date to the 17th century: William Petty in estimated world population at million modern estimates ranging close to twice this number ; by the late 18th century, estimates ranged close to one billion consistent with modern estimates. Classical demography and Medieval demography Estimates of the population of the world at the time agriculture emerged in around 10, BC have ranged between 1 million and 15 million.
Manual and medical devices reporting: Detecting and evaluating drug safety signals Monitoring safety of medicative products during product life cycle.
Different ways to signal detection including traditional methods and data mining methods? Approaching statistical and analytic methods to detect, prioritize and evaluate signals in an efficient and proactive manner Moderator: Pharmacovigilance and risk management planning Address uniformity and differences in risk Csr in banking sector of bd design in the ICH regions and other jurisdictions Identify the differences between important identified risks and important potential risks Marketing authorisation for medicines that do not have RMP Discussing the standard scheme and contents of Indian RMP in context of a risk management system and risk evaluation and mitigation strategy Discuss primary and non-routine tools for handle product risks, how the potency of selected tool is evaluated, and points to focus for the modification, revision, or release of a given non-routine intervention Discussing the standard sector of the regulatory models for pv in the environment of risk management planning and on the realistic feature of coping biopharmaceutical product risks in the context of benefits and the healthcare delivery system Moderator: Current regulatory framework and expectations for good pharmacovigilance practices Marketing authorisation bearers with a goal of publicizing single DHPC in state where numerous marketing authorisation bearers are focused Explanation on the GVP modules and newly revised GVP structures Distinct level of info and knowledge although sustaining the quality and consistency of the information Having the requisite quality of coordination and cooperation among the different parties involved in issuing safety communications Advantages of medicine including the relevancy info on the seriousness, severity, frequency, risk factors, time to onset, reversibility of potential adverse reactions and expected time to recovery Doubtless concern to safety factor especially while qualified parties are executing their evaluations Moderator: Mayur Parmar is working as Deputy collector with Govt of Gujarat.
He is carrying six years of rich experience and during his tenure he has inspected various Drug manufacturing sites, drugs Distribution sites, hospitals, blood banks and blood storage centres as per Indian as well as WHO guidelines.
With six years of experience of Drug Regulation, Mayur has investigated more than NSQ drugs and launched Prosecution for spurious and misbranded drugs. Prior to it Mayur has completed his M. Pharm with specialization in New Drug Delivery System from Maharaja Sayajirao university of Baroda, Gujarat with two gold medals for securing first rank in the university.
He has published four research papers in International and National journals. His views on Pharma regulations have been published in various magazines like eHealth and others. He is pursuing his Ph. D in New Drug Delivery System.
He has chaired two international conferences and speaked at various national and international forums. He is having industrial experience in formulation development and Intellectual property management.
A Huge believer of lifetime learning - Mayur constantly strives to improve himself, both on personal and professional front. Prasad Deshmukh, is working as Director in global safety and Pharmacovigilance department in Syneos Health. He has over than 14 years of experience in Drug Safety and PV activities and clinical practice.
He would be talking about Challenges for good pharmacovigilance practices for the generic industry. How to overcome them? He has three decades of experience, initially in consumer marketing in India and Nigeria with Voltas and Colgate Palmolive, and later in technology in North America and India with early stage as well as relatively more established companies, including UCA Services later Mphasis, a Hewlett Packard company.
Amrit is a Homeopathic Physician by qualification. With stint as clinician for initial years, she also holds Post Graduate Diploma in Pharmacovigilance. She has almost 15 years of industry experience with 10 years concentrated in pharmacovigilance.
She began her journey with a successful stint with APCER where she achieved excellence in management of Pharmacovigilance with extensive knowledge of various Pharmacovigilance data bases, systems and processes. She has a comprehensive 6 years in strong project management Project scope, timelines, quality, costpeople management handling larger teams for multiple projectsperforming active client engagement, providing subject matter expertise support during prospective client visit and meetings, ICH-GCP guidelines and Good Pharmacovigilance practice complaint.
Promoted as Joint Commissioner in March Expert in Detection and investigation of various cases related to spurious drugs and other violations of Drugs and Cosmetics Act.
He has managed clinical development of novel molecular entities in diverse therapeutic areas in all clinical development phases. Dr Bhatt has worked as a consultant in pharmaceutical medicine and clinical pharmacology. Dr Bhatt is the recipient of Drug Information Association outstanding Service award for his immense contributions in his field of specialization.The banks and NBFIs will have to use 30 per cent of total CSR expenditure in the education sector for the underprivileged population, according to the central bank circular.
The expenditure should be for scholarships and stipends for students from low-income family in reputed academic and vocational training institutions. Agrani Bank Limited (ABL) is the largest government commercial bank in Bangladesh addresses social concerns that threaten the structure of society and redress social conditions that adversely affect the well-being of people and society of Bangladesh.
Banking industry in Bangladesh is now a day very prospective and competitive. To give a competitive edge, CSR is a very strong and helpful tool.
The objective of the study is to investigate a definite structure and concept of Corporate Social Responsibility (CSR) in the area of banking sector.
It deals with early history of corporate social responsibility, banking mission, and the area of social welfare.
This event marked the launch of a new report by The Harvard Kennedy School's CSR Initiative (CSRI) and Business Fights Poverty: “Sustaining and Scaling the Impact of Enterprise Development Programmes”, which draws on SABMiller’s experience.
a. Education Support Program: Believing education as a tool for social change, Prime Bank Foundation is proud to have another year of success of its Education Support Program launched in It is a long term, renewable scholarship program for underprivileged but meritorious students from .
Although Bombardier lost the huge Transnet contract to China South Rail (CSR) — which leaked e-mails showed paid the Gupta family Rbn in kickbacks to clinch the deal — it did sell a.